CRMD Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
101.9M
-20.0%
127.4M
-0.9%
128.6M
+23.3%
104.3M
+162.4%
39.7M
Cost of Revenue
24.8M
+11.2%
22.3M
+4.7%
21.3M
+90.3%
11.2M
+501.2%
1.9M
Gross Profit
77.1M
-26.6%
105.1M
-2.0%
107.3M
+15.3%
93.1M
+145.8%
37.9M
Operating Expenses
34.3M
-17.8%
41.7M
-13.4%
48.2M
+15.4%
41.7M
+138.2%
17.5M
R&D
6.7M
-7.3%
7.2M
-16.1%
8.6M
+68.7%
5.1M
+108.7%
2.4M
SG&A
27.5M
-19.6%
34.3M
-13.5%
39.6M
+8.0%
36.6M
+130.6%
15.9M
Operating Income
42.8M
-32.4%
63.4M
+7.2%
59.1M
+15.2%
51.3M
+152.3%
20.4M
EBITDA
53.4M
-27.8%
73.9M
+6.3%
69.6M
+26.2%
55.1M
+168.8%
20.5M
Net Income
26.0M
-32.7%
38.6M
+175.3%
14.0M
-87.1%
108.6M
+447.5%
19.8M
EPS (Basic)
$0.33
-31.2%
$0.48
+166.7%
$0.18
-87.3%
$1.42
+389.7%
$0.29
EPS (Diluted)
$0.29
-32.6%
$0.43
+186.7%
$0.15
-88.1%
$1.26
+350.0%
$0.28
Shares (Diluted)
92.5M
-0.5%
93.0M
-1.2%
94.1M
+9.2%
86.2M
+19.9%
71.9M
CorMedix (CRMD) โ€” Financials